Significant Changes in Endogenous Retinal Gene Expression Assessed 1 Year After a Single Intraocular Injection of AAV-CNTF or AAV-BDNF

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2016 Dec 10

PMID 27933306

Citations 18

Authors

Chrisna J LeVaillant

Anil Sharma

Jill Muhling

Lachlan Pg Wheeler

Greg S Cozens

Mats Hellstrom

Jennifer Rodger

Alan R Harvey

Affiliations

Soon will be listed here.

Abstract

Use of viral vectors to deliver therapeutic genes to the central nervous system holds promise for the treatment of neurodegenerative diseases and neurotrauma. Adeno-associated viral (AAV) vectors encoding brain-derived neurotrophic factor (BDNF) or ciliary derived neurotrophic factor (CNTF) promote the viability and regeneration of injured adult rat retinal ganglion cells. However, these growth-inducing transgenes are driven by a constitutively active promoter, thus we examined whether long-term AAV-mediated secretion of BDNF or CNTF affected endogenous retinal gene expression. One year after the intravitreal injection of AAV-green fluorescent protein (GFP), bi-tronic AAV-BDNF-GFP or AAV-CNTF-GFP, mRNA was extracted and analyzed using custom 96 well polymerase chain reaction arrays. Of 93 test genes, 56% showed significantly altered expression in AAV-BDNF-GFP and/or AAV-CNTF-GFP retinas compared with AAV-GFP controls. Of these genes, 73% showed differential expression in AAV-BDNF versus AAV-CNTF injected eyes. To focus on retinal ganglion cell changes, quantitative polymerase chain reaction was undertaken on mRNA (16 genes) obtained from fixed retinal sections in which the ganglion cell layer was enriched. The sign and extent of fold changes in ganglion cell layer gene expression differed markedly from whole retinal samples. Sustained and global alteration in endogenous mRNA expression after gene therapy should be factored into any interpretation of experimental/clinical outcomes, particularly when introducing factors into the central nervous system that require secretion to evoke functionality.

Citing Articles

Eurycomanone from Jack upregulates neurotrophin-3 gene expression in retinal Müller cells .

Sakai Y, Yamada M, Watanabe T, Yamazaki A, Furukawa M, Izumo N J Clin Biochem Nutr. 2024; 74(3):199-206.

PMID: 38799139 PMC: 11111470. DOI: 10.3164/jcbn.23-73.

Therapeutic strategies for glaucoma and optic neuropathies.

Lo J, Mehta K, Dhillon A, Huang Y, Luo Z, Nam M Mol Aspects Med. 2023; 94:101219.

PMID: 37839232 PMC: 10841486. DOI: 10.1016/j.mam.2023.101219.

Intravitreal Injection of AAV for the Transduction of Mouse Retinal Ganglion Cells.

Nieuwenhuis B, Osborne A Methods Mol Biol. 2023; 2708:155-174.

PMID: 37558970 DOI: 10.1007/978-1-0716-3409-7_17.

A Novel Multi-Observation System to Study the Effects of Anterior Ocular Inflammation in Zinn's Zonule Using One Specimen.

Takahashi A, Arima T, Toda E, Kobayakawa S, Shimizu A, Takahashi H Int J Mol Sci. 2023; 24(7).

PMID: 37047225 PMC: 10093946. DOI: 10.3390/ijms24076254.

Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters.

Nieuwenhuis B, Laperrousaz E, Tribble J, Verhaagen J, Fawcett J, Martin K Gene Ther. 2023; 30(6):503-519.

PMID: 36635457 PMC: 10284706. DOI: 10.1038/s41434-022-00380-z.

References

Nagai J, Kitamura Y, Owada K, Yamashita N, Takei K, Goshima Y . Crmp4 deletion promotes recovery from spinal cord injury by neuroprotection and limited scar formation. Sci Rep. 2015; 5:8269. PMC: 4317684. DOI: 10.1038/srep08269. View

Leaver S, Cui Q, Plant G, Arulpragasam A, Hisheh S, Verhaagen J . AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells. Gene Ther. 2006; 13(18):1328-41. DOI: 10.1038/sj.gt.3302791. View

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

OConnor D, Boulis N . Gene therapy for neurodegenerative diseases. Trends Mol Med. 2015; 21(8):504-12. DOI: 10.1016/j.molmed.2015.06.001. View

You S, Hellstrom M, Pollett M, LeVaillant C, Moses C, Rigby P . Large-scale reconstitution of a retina-to-brain pathway in adult rats using gene therapy and bridging grafts: An anatomical and behavioral analysis. Exp Neurol. 2016; 279:197-211. DOI: 10.1016/j.expneurol.2016.03.006. View

Park K, Hu Y, Muhling J, Pollett M, Dallimore E, Turnley A . Cytokine-induced SOCS expression is inhibited by cAMP analogue: impact on regeneration in injured retina. Mol Cell Neurosci. 2009; 41(3):313-24. DOI: 10.1016/j.mcn.2009.04.002. View

Maguire C, Ramirez S, Merkel S, Sena-Esteves M, Breakefield X . Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics. 2014; 11(4):817-39. PMC: 4391389. DOI: 10.1007/s13311-014-0299-5. View

de Winter F, Hoyng S, Tannemaat M, Eggers R, Mason M, Malessy M . Gene therapy approaches to enhance regeneration of the injured peripheral nerve. Eur J Pharmacol. 2013; 719(1-3):145-152. DOI: 10.1016/j.ejphar.2013.04.057. View

Bartus R, Weinberg M, Samulski R . Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther. 2013; 22(3):487-497. PMC: 3944322. DOI: 10.1038/mt.2013.281. View

10.

Hellstrom M, Ruitenberg M, Pollett M, Ehlert E, Twisk J, Verhaagen J . Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection. Gene Ther. 2008; 16(4):521-32. DOI: 10.1038/gt.2008.178. View

11.

Marks Jr W, Baumann T, Bartus R . Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer. Hum Gene Ther. 2015; 27(7):522-7. DOI: 10.1089/hum.2015.134. View

12.

Klein R, Muir D, King M, Peel A, Zolotukhin S, Moller J . Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience. 1999; 90(3):815-21. DOI: 10.1016/s0306-4522(98)00537-5. View

13.

Lipinski D, Thake M, MacLaren R . Clinical applications of retinal gene therapy. Prog Retin Eye Res. 2012; 32:22-47. DOI: 10.1016/j.preteyeres.2012.09.001. View

14.

Koilkonda R, Yu H, Chou T, Feuer W, Ruggeri M, Porciatti V . Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol. 2014; 132(4):409-20. PMC: 4266107. DOI: 10.1001/jamaophthalmol.2013.7630. View

15.

Smith P, Sun F, Park K, Cai B, Wang C, Kuwako K . SOCS3 deletion promotes optic nerve regeneration in vivo. Neuron. 2009; 64(5):617-23. PMC: 2796263. DOI: 10.1016/j.neuron.2009.11.021. View

16.

Mizuguchi H, Xu Z, Uchida E, Hayakawa T . IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther. 2000; 1(4):376-82. DOI: 10.1006/mthe.2000.0050. View

17.

Boyle E, Weng S, Gollub J, Jin H, Botstein D, Cherry J . GO::TermFinder--open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics. 2004; 20(18):3710-5. PMC: 3037731. DOI: 10.1093/bioinformatics/bth456. View

18.

Hellstrom M, Pollett M, Harvey A . Post-injury delivery of rAAV2-CNTF combined with short-term pharmacotherapy is neuroprotective and promotes extensive axonal regeneration after optic nerve trauma. J Neurotrauma. 2011; 28(12):2475-83. DOI: 10.1089/neu.2011.1928. View

19.

Tuszynski M, Thal L, Pay M, Salmon D, U H, Bakay R . A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005; 11(5):551-5. DOI: 10.1038/nm1239. View

20.

Uchida K, Nakajima H, Guerrero A, Johnson W, Masri W, Baba H . Gene therapy strategies for the treatment of spinal cord injury. Ther Deliv. 2014; 5(5):591-607. DOI: 10.4155/tde.14.20. View